biosci-rc.com
Mutant KRAS vaccines for pancreatic cancer under clinical development – Bioscience Resources Consulting
https://biosci-rc.com/2016/12/15/mutant-kras-vaccines-for-pancreatic-cancer-under-clinical-development
Research and Development Analysis, Creating Value Based on Innovation. Mutant KRAS vaccines for pancreatic cancer under clinical development. Are developing vaccines that contain KRAS mutant peptides for patients with pancreatic cancer. These vaccines involve injection of the peptides and subsequent. GlobeImmune’s product is clinically more advanced with efficacy shown in a subset of pancreatic pancreatic cancer patients in a phase II clinical trial (see. KRAS vaccine combination strategies with agents t...
biosci-rc.com
Science – Bioscience Resources Consulting
https://biosci-rc.com/tag/science
Research and Development Analysis, Creating Value Based on Innovation. I consult for a number of ongoing biotechnology R&D projects (Athla LLC, LPBI group). Get in touch for troubleshooting/ insight within your discovery phase/ preclinical research program and for program development consultation. Is an angel investment platform exclusively focused on funding ‘deep technology’ startups – companies founded on a scientific discovery or meaningful engineering innovation. I provide the following:. Speirs V; ...
biosci-rc.com
David Orchard-Webb – Bioscience Resources Consulting
https://biosci-rc.com/author/daveowebb
Research and Development Analysis, Creating Value Based on Innovation. I consult for a number of ongoing biotechnology R&D projects (Athla LLC, LPBI group). Get in touch for troubleshooting/ insight within your discovery phase/ preclinical research program and for program development consultation. Is an angel investment platform exclusively focused on funding ‘deep technology’ startups – companies founded on a scientific discovery or meaningful engineering innovation. I provide the following:. Speirs V; ...
rnaventures.blogspot.com
Colorado Life Science Deal Flow: Tape-Delay from the RMLSIC | Part Deux
http://rnaventures.blogspot.com/2009/09/tape-delay-from-rmlsic-part-deux.html
Monday, September 21, 2009. Tape-Delay from the RMLSIC Part Deux. Continuing here with Part Deux of the Rocky Mountain Life Science Investor Conference presenting companies. Yesterday CLSDF posted the Diagnostic. Oriented entities, today we feature the biopharma folks. 8211; Ft. Collins, CO-based IV is focused on vaccines against emerging worldwide infectious diseases. Compounds queued up for clinical trials includes DENVax against dengue, HFMDVax against hand, foot and mouth disease and JEVax fo...8211;...
biovoice.blogspot.com
BIO Voice: Tuesday Day 3: Groovin' Right Along...
http://biovoice.blogspot.com/2007/05/tuesday-day-3-groovin-right-along.html
Tuesday, May 8, 2007. Tuesday Day 3: Groovin' Right Along. I was intrigued by the title of this morning’s business development. Tract – Risky Business: Risk Reduced Models for the Biotech Industry. 8211; so I jumped ship from my finance focus and was not disappointed. What a lively and interesting dialogue by the CEO panelists ( Steve Kelly. 8211; Innovive Pharma, Scott Cormack. 8211; OncoGeneX, Jay Lichter. 8211; Akesis Pharma and the very entertaining Rajesh Shrotriya. It did not disappoint. System is ...
healthcapital.ch
Investments / Home Page - Healthcapital
http://www.healthcapital.ch/index.php/site/Investments
The following investments were performed on behalf of our partners. Http:/ www.telormedix.com. Http:/ www.specialityeuropeanpharma.com/. Http:/ www.globeimmune.com/. Http:/ www.visioncareinc.net/. On biotech investments and healthcare management worldwide. World healthcare policy advisory. A global healthcare policy think-tank.
lightstonevc.com
Our Portfolio Of Bright Futures | Lightstone Ventures
http://www.lightstonevc.com/portfolio/all
Our portfolio of bright futures. The following active life science portfolio companies and select exits are, or were, managed by members of the Lightstone team in the healthcare portfolios of Morgenthaler and/or ATV as indicated. Acceleron Pharma is a biopharmaceutical company focused on the development and commercialization of novel protein therapeutics for orphan diseases and cancer based on the TGF-β protein superfamily. Location: Cambridge, MA. Location: Dublin, Ireland. Location: Burlingame, CA.
rnaventures.blogspot.com
Colorado Life Science Deal Flow: GlobeImmune | Presenting Phase II Data @ AASLD
http://rnaventures.blogspot.com/2009/10/globeimmune-presenting-phase-ii-data.html
Tuesday, October 06, 2009. GlobeImmune Presenting Phase II Data @ AASLD. Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“ GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients. 31 Oct. to 4 Nov. 2009 Boston, MA). Plus peg-interferon ( peg- IFN. Labels: CO Private: GlobeImmune. Focuses upo...